196 related articles for article (PubMed ID: 30326894)
1. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse.
Ai C; Zhang S; He Q; Shi J
Lipids Health Dis; 2018 Oct; 17(1):239. PubMed ID: 30326894
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
Yu M; Liang C; Kong Q; Wang Y; Li M
Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
[TBL] [Abstract][Full Text] [Related]
3. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
[TBL] [Abstract][Full Text] [Related]
4. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
5. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
Lee SA; Hong SJ; Sung JH; Kim KS; Kim SH; Cho JM; Chun SW; Lee SR; Kim CS; Kim TN; Kim DH; Park HC; Kim BJ; Kim HS; Choi JY; Hong YJ; Chung JW; Yoon SB; Lee SH; Lee CW
Medicine (Baltimore); 2023 Nov; 102(47):e36122. PubMed ID: 38013289
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
[TBL] [Abstract][Full Text] [Related]
8. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.
Lee SA; Kim W; Hong TJ; Ahn Y; Kim MH; Hong SJ; Kim BS; Kim SY; Chae IH; Kim BJ; Rhee MY; Shin JH; Kang TS; Cho JM; Kim JS; Lee CW
Clin Ther; 2021 Sep; 43(9):1573-1589. PubMed ID: 34429197
[TBL] [Abstract][Full Text] [Related]
9. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.
Bays HE; Chen E; Tomassini JE; McPeters G; Polis AB; Triscari J
Fundam Clin Pharmacol; 2015 Apr; 29(2):209-18. PubMed ID: 25431239
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis.
Mikhailidis DP; Lawson RW; McCormick AL; Sibbring GC; Tershakovec AM; Davies GM; Tunceli K
Curr Med Res Opin; 2011 Jun; 27(6):1191-210. PubMed ID: 21473671
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy.
Rhee MY; Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HY; Kim HS
Clin Ther; 2019 Dec; 41(12):2571-2592. PubMed ID: 31727361
[TBL] [Abstract][Full Text] [Related]
13. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Ballantyne CM; Blazing MA; King TR; Brady WE; Palmisano J
Am J Cardiol; 2004 Jun; 93(12):1487-94. PubMed ID: 15194018
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy].
Alonso R; Fernández de Bobadilla J; Méndez I; Lázaro P; Mata N; Mata P
Rev Esp Cardiol; 2008 Apr; 61(4):382-93. PubMed ID: 18405519
[TBL] [Abstract][Full Text] [Related]
16. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
17. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Awad K; Mikhailidis DP; Katsiki N; Muntner P; Banach M;
Drugs; 2018 Mar; 78(4):453-462. PubMed ID: 29396832
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials.
Pandor A; Ara RM; Tumur I; Wilkinson AJ; Paisley S; Duenas A; Durrington PN; Chilcott J
J Intern Med; 2009 May; 265(5):568-80. PubMed ID: 19141093
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.
Olszewska-Banaszczyk M; Jackowska P; Gorzelak-Pabiś P; Pytel E; Koter-Michalak M; Broncel M
Pharmacol Rep; 2018 Apr; 70(2):258-262. PubMed ID: 29475008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
